Combined Serum GFAP and Neurofilament Light Chain (NfL) Stratifies Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis
Study Design & Technical Specifications
Sample Size / Cohort
1,420 Patients
Subject / Study Model
CNS Experimental / Clinical Model
Analytical Modalities
Primary Abstract & Repository Description
Source: medRxiv (Neurology)Editorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
This resource from medRxiv (Neurology) ("Combined Serum GFAP and Neurofilament Light Chain (NfL) Stratifies Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis") addresses critical scientific questions within Multiple Sclerosis (MS). Research in this domain currently faces major translational bottlenecks, including progression independent of relapse activity (PIRA), smoldering neuroinflammation, and remyelination failure across white and cortical gray matter. By focusing on key thematic elements (Multiple Sclerosis, PIRA, GFAP, NfL, PRL), this work contributes empirical evidence toward understanding how molecular, cellular, or systems-level alterations relate to core disease pathways such as paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Integrating these findings into the broader open science ecosystem helps reduce fragmentation across independent laboratories and accelerates hypothesis verification.
2. Study Architecture & Findings
Methodologically, this preprint integrates Serum Biomarkers (Simoa), 3T FLAIR / SWI MRI, EDSS within a CNS Experimental / Clinical Model framework (1,420 Patients). Curated via medRxiv (Neurology), the analytical approach provides structured insights into Multiple Sclerosis (MS) pathophysiology. Evaluating the reported outcomes alongside Serum Biomarkers (Simoa), 3T FLAIR / SWI MRI, EDSS technical specifications allows researchers to benchmark effect sizes, assay sensitivity, and experimental reproducibility against established reference cohorts.
3. Secondary Analysis & Reusability
Researchers and computational neuroscientists can reuse this resource across multiple secondary workflows: (1) Cross-Cohort Harmonization & Meta-Analysis — combining these Serum Biomarkers (Simoa), 3T FLAIR / SWI MRI, EDSS records with complementary repositories (such as OpenNeuro, DANDI, Agora, or Europe PMC) to increase statistical power; (2) Computational Benchmarking & Machine Learning — utilizing the documented features (Multiple Sclerosis, PIRA, GFAP, NfL, PRL) as training, validation, or out-of-distribution test sets for predictive biomarker discovery in Multiple Sclerosis (MS); and (3) Experimental Protocol Alignment — referencing the study design (CNS Experimental / Clinical Model, 1,420 Patients) to calibrate sample size calculations (power analysis) and endpoint selection for upcoming preclinical or clinical studies.
4. Methodological Caveats & Governance
Because this record is indexed as a preprint, its experimental conclusions have not yet completed formal journal peer review; downstream clinical or therapeutic decisions should await peer-reviewed validation. Specifically, when interpreting Serum Biomarkers (Simoa), 3T FLAIR / SWI MRI, EDSS results in Multiple Sclerosis (MS), researchers must control for confounding variables (such as age, sex, post-mortem interval, scanner/instrument drift, or medication state) and verify compliance with open-access attribution requirements (CC-BY 4.0).
Data Access, Reproducibility & Analysis Starter Guide
BIDS (Brain Imaging Data Structure) v1.9+
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.
Tags & Modalities
Bibliometrics, Peer-Review Status & Citation Export
Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv
1. Citation Metrics & Context Breakdown
Citation Context Breakdown
2. Peer-Review Validation & Revision History
Preprint Article (bioRxiv / medRxiv — Awaiting Peer Review)
This article is indexed as an unrefereed preprint. Our ingestion pipeline periodically queries Europe PMC and bioRxiv/medRxiv APIs to automatically link the final peer-reviewed journal DOI once published.
3. Standardized Academic Citation & BibTeX Export
Barro C et al. (2026). Combined Serum GFAP and Neurofilament Light Chain (NfL) Stratifies Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis. medRxiv (Neurology). https://www.medrxiv.org/collection/neurology
@article{c2026medr,
title = {Combined Serum GFAP and Neurofilament Light Chain (NfL) Stratifies Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis},
author = {Barro C and Benkert P and Kuhle J and Swiss MS Cohort Study},
year = {2026},
journal = {medRxiv (Neurology)},
howpublished = {\url{https://www.medrxiv.org/collection/neurology}},
doi = {},
note = {CNS Open Data: multiple_sclerosis}
}Related Multiple Sclerosis Research & Datasets
Explore All DatasetsMSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».
Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...
MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis
The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.
MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)
A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.
Active Clinical Trials & Pipeline in Multiple Sclerosis
View Clinical PipelineMSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
MSDA: GDSI Mock DataGenerator - GDSI Mock data generator
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.